- Home
- TRIP vs TARS Comparison
TRIP vs TARS Comparison
Compare TRIP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- TARS
- Stock Information
- Founded
- TRIP 2000
- TARS 2016
- Country
- TRIP United States
- TARS United States
- Employees
- TRIP N/A
- TARS 323
- Industry
- TRIP Computer Software: Programming Data Processing
- TARS Medicinal Chemicals and Botanical Products
- Sector
- TRIP Technology
- TARS Health Care
- Exchange
- TRIP Nasdaq
- TARS Nasdaq
- Market Cap
- TRIP 2.1B
- TARS 1.7B
- IPO Year
- TRIP 2011
- TARS 2020
- Fundamental
- Price
- TRIP $16.40
- TARS $41.91
- Analyst Decision
- TRIP Hold
- TARS Strong Buy
- Analyst Count
- TRIP 14
- TARS 7
- Target Price
- TRIP $17.73
- TARS $67.14
- AVG Volume (30 Days)
- TRIP 3.2M
- TARS 574.0K
- Earning Date
- TRIP 08-07-2025
- TARS 08-11-2025
- Dividend Yield
- TRIP N/A
- TARS N/A
- EPS Growth
- TRIP 115.16
- TARS N/A
- EPS
- TRIP 0.37
- TARS N/A
- Revenue
- TRIP $1,838,000,000.00
- TARS $233,674,000.00
- Revenue This Year
- TRIP $7.52
- TARS $122.94
- Revenue Next Year
- TRIP $7.50
- TARS $44.14
- P/E Ratio
- TRIP $43.53
- TARS N/A
- Revenue Growth
- TRIP 1.44
- TARS 449.03
- 52 Week Low
- TRIP $10.43
- TARS $20.08
- 52 Week High
- TRIP $18.66
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- TRIP 46.48
- TARS 52.82
- Support Level
- TRIP $16.15
- TARS $38.51
- Resistance Level
- TRIP $18.04
- TARS $43.33
- Average True Range (ATR)
- TRIP 0.60
- TARS 1.74
- MACD
- TRIP -0.30
- TARS -0.03
- Stochastic Oscillator
- TRIP 10.64
- TARS 48.78
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.